Australia’s GMiA launches a Guide to Biosimilars
The Australian Generic Medicines Industry Association (GMiA) has today launched the GMiA Guide to Biosimilars during a Parliamentary Friends of Medicine event at Parliament House.
The GMiA Guide to Biosimilars aims to provide a concise reference for explaining this emerging class of affordable medicines, presenting the facts in a user-friendly format.
Biological medicines have revolutionized the management of some of the most difficult to treat diseases including cancer, multiple sclerosis and autoimmune diseases. However, biological medicines are very costly to the Pharmaceutical Benefits Scheme (PBS), which may limit their availability to some patients, the GMiA noted. Biosimilars are a subclass of biological medicines that offer therapeutically equivalent and more cost effective alternatives to existing, high-cost biological medicines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze